Are you living with IgA nephropathy?
The BEYOND study is a phase 3, randomized, double-blind, placebo-controlled study of zigakibart
(BION-1301) in adults with IgA nephropathy (IgAN). The BEYOND study is a clinical trial that will
test an investigational drug named zigakibart which is being developed for the treatment of
IgAN. The goal of the study is to see if zigakibart has an effect on how well your kidneys work by
measuring the level of protein in your urine (proteinuria) and how well your kidneys are filtering
blood (estimated glomerular filtration rate also known as eGFR). The study is also planning to see
if zigakibart is safe and well tolerated in patients with IgAN.
About 292 adults will take part in this study worldwide. This study will be conducted at about
200 study centers worldwide. Participation in the study involves up to 57 visits over the course of
31 months (about 2 and a half years). Participants who qualify may be reimbursed for their time
and travel costs like mileage and lodging for taking part in the clinical study.
Who Can Join?
You may qualify to participate in this study if you are:
- Age 18 and older
- Have been diagnosed with IgA nephropathy by kidney biospy.
- Have urine containing total protein levels of ≥ 1.0 g/day and a urine protein creatinine ratio (UPCR) of ≥ 0.7 g/g
- eGFR of >/= 30 mL/min/1.73 m2
- Willingness to use contraception
Learn more by visiting: https://clinicaltrials.gov/study/NCT05852938